Catena Biosciences specializes in innovative protein coupling technology to develop advanced therapeutics. Their platform enables the attachment of any two soluble proteins using an enzyme and native amino acids, without size or complexity restrictions. This versatile approach has applications in modifying cancer-specific antibodies, CRISPR proteins, and cell surfaces, offering potential for a wide range of medical treatments.
The company's vision is to revolutionize therapeutic development by making biologic construction as flexible as small molecule synthesis. Catena's technology allows for the creation of modular protein therapeutics, expanding possibilities in antibody-drug conjugates and functional antibody engineering. This approach aims to overcome current limitations in biologic structures, potentially opening new avenues for treating various medical conditions.
